Devgen receives IWT grant to support its obesity drug discovery program
27-Feb-2007
In its obesity program, Devgen takes a multidisciplinary approach to validate a novel class of kinase targets. According to the company, IWT's support for this program is very important for Devgen, not only from a funding perspective, but it is an endorsement of the innovative approach and validation opportunities of this program. The funding covers a period of 16 months.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.